WILLIAM G WIERDA to CD52 Antigen
This is a "connection" page, showing publications WILLIAM G WIERDA has written about CD52 Antigen.
Connection Strength
0.181
-
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb; 148(3):386-93.
Score: 0.087
-
Immunotherapy of chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2001 Jun; 1(1):73-83.
Score: 0.049
-
Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51.
Score: 0.017
-
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 Dec 15; 98(12):2657-63.
Score: 0.014
-
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5.
Score: 0.014